Evidence map›Paper›PMID 29508455›Full record

ReviewMovement disorders : official journal of the Movement Disorder Society2018

Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.

Jose-Alberto Palma, Horacio Kaufmann

Open access · greenAbstract readReview
In one paragraph

Review in Movement disorders : official journal of the Movement Disorder Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 3 pooled it
18.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 3 syntheses or guidelines pooled it, 237 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2026
    Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. A Pragmatic Approach to Sexual Health in Movement Disorders.Movement disorders clinical practice · 2025
    Review
  16. Article
  17. Association between ultra-short heart rate variability and risk of Parkinson's disease: a prospective cohort study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Article
  18. Article
  19. Article
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jose-Alberto PalmaDepartment of Neurology, Dysautonomia Center, New York University School of Medicine, New York, New York, USA.ORCID 0000-0002-1345-6774
Horacio KaufmannDepartment of Neurology, Dysautonomia Center, New York University School of Medicine, New York, New York, USA.
Dysautonomia Foundation · US

Funding

Training CoreU54NS065736 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI KAUFMANN, HORACIO · 2009 to 2018
$11.6M
Optimization of compounds to improve mRNA splicing in familial dysautonomiaU01NS078025 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI SLAUGENHAUPT, SUSAN A · 2012 to 2016
$1.3M
NINDS NIH HHS U01 NS078025NINDS NIH HHS U54 NS065736
6 · The paper itself

Abstract

Dysfunction of the autonomic nervous system afflicts most patients with Parkinson disease and other synucleinopathies such as dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, reducing quality of life and increasing mortality. For example, gastrointestinal dysfunction can lead to impaired drug pharmacodynamics causing a worsening in motor symptoms, and neurogenic orthostatic hypotension can cause syncope, falls, and fractures. When recognized, autonomic problems can be treated, sometimes successfully. Discontinuation of potentially causative/aggravating drugs, patient education, and nonpharmacological approaches are useful and should be tried first. Pathophysiology-based pharmacological treatments that have shown efficacy in controlled trials of patients with synucleinopathies have been approved in many countries and are key to an effective management. Here, we review the treatment of autonomic dysfunction in patients with Parkinson disease and other synucleinopathies, summarize the nonpharmacological and current pharmacological therapeutic strategies including recently approved drugs, and provide practical advice and management algorithms for clinicians, with focus on neurogenic orthostatic hypotension, supine hypertension, dysphagia, sialorrhea, gastroparesis, constipation, neurogenic overactive bladder, underactive bladder, and sexual dysfunction. © 2018 International Parkinson and Movement Disorder Society.

Indexed as

Autonomic Nervous System DiseasesHumansParkinson DiseaseSynucleinsSynucleinsautonomic failuredysautonomiamultiple system atrophynonmotor symptomsParkinson's diseasetreatment

Identifiers

PMID29508455
PMCPMC5844369
OpenAlexW2792783253

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.